Search results
Showing 76 to 85 of 85 results for infliximab
Etanercept and infliximab for the treatment of psoriatic arthritis (TA104)
This guidance has been replaced by NICE technology appraisal guidance 199.
Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis (TA130)
This guidance has been updated and replaced by NICE technology appraisal guidance 375.
Obinutuzumab for untreated advanced follicular lymphoma (TA513)
Evidence-based recommendations on obinutuzumab (Gazyvaro) for untreated advanced follicular lymphoma in adults.
The clinical effectiveness and cost effectiveness of infliximab for Crohn's disease (TA40)
This guidance has been updated and replaced by NICE technology appraisal guidance 187.
Adalimumab and dexamethasone for treating non-infectious uveitis (TA460)
Evidence-based recommendations on adalimumab (Humira) and dexamethasone (Ozurdex) for treating non-infectious uveitis in adults.
Discontinued [GID-TAG402]
Apremilast for treating moderate to severe plaque psoriasis (TA419)
Evidence-based recommendations on apremilast (Otezla) for treating moderate to severe plaque psoriasis in adults.
effectiveness of methotrexate, ciclosporin, tacrolimus, adalimumab and infliximab compared with each other and with placebo for...
NICE recommends several treatment options to help with rheumatoid arthritis
Around 25,000 people with moderate rheumatoid arthritis that has not responded to conventional therapies are set to benefit from the recommendations announced today.